Satellite Meetings at RSNA for Providers Interested in TMIST

November 24, 2016
Diagnostic Imaging Staff
Diagnostic Imaging Staff

Large-scale breast cancer screening trial will compare tomosynthesis and digital mammography.

The Tomosynthesis Mammography Imaging Screening Trial (TMIST) by the ECOG-AGRIN Cancer Research Group is now recruiting medical facilities with an estimated open trial date of mid 2017.

The first large-scale breast cancer screening trial in nearly 25 years has been approved for funding by the National Cancer Institute and will enroll 165,000 asymptomatic women in the U.S. and Canada between ages 45 and 74. The trial is aimed at comparing the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis vs. standard digital mammography.

TMIST will require nearly 100 sites with an estimated four to five women per day to reach the accrual goal in three years, according to a release.

Participation eligibility includes:

U.S.- or Canada-based medical facility

Able to provide digital breast tomosynthesis and standard digital mammography in the same location

Member of a research group in the NCI National Clinical Trials Network (NCTN) either directly or through the NCI Community Oncology Research Program (NCORP)

Interested medical providers can attend one of two available TMIST information sessions at RSNA 2016:

TMIST Satellite Session One

Monday, Nov. 28, 1:30-2:30 in McCormick Place – W470a

TMIST Satellite Session Two

Wednesday, Nov. 30, 11:00-12:00 in McCormick Place – W192b

Preregistration is not required.